Roche's anti-TIGIT drug, tiragolumab, failed to demonstrate a life-extending benefit in a Phase 3 trial for non-small cell lung cancer, raising concerns about the TIGIT inhibitor class.
The combination of domvanalimab and zimberelimab demonstrated a statistically significant improvement in overall survival (OS) compared to zimberelimab alone in advanced NSCLC patients.
Arcus Biosciences and AstraZeneca are collaborating to evaluate casdatifan, a HIF-2a inhibitor, with volrustomig, a PD-1/CTLA-4 bispecific antibody, for ccRCC treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.